4//SEC Filing
Shannon John Patrick Jr 4
Accession 0001553595-25-000004
CIK 0001867096other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 5:58 PM ET
Size
12.5 KB
Accession
0001553595-25-000004
Insider Transaction Report
Form 4
Shannon John Patrick Jr
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-13$1.55/sh+8,970$13,904→ 2,666,395 total - Exercise/Conversion
Common Stock
2025-11-14$1.55/sh+87,100$135,005→ 2,730,253 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-13−8,970→ 151,365 totalExercise: $1.55Exp: 2027-02-03→ Common Stock (8,970 underlying) - Sale
Common Stock
2025-11-13$7.46/sh−23,242$173,402→ 2,643,153 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-14−87,100→ 64,265 totalExercise: $1.55Exp: 2027-02-03→ Common Stock (87,100 underlying)
Footnotes (3)
- [F1]The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001553595
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 5:58 PM ET
- Size
- 12.5 KB